INCHEON, South Korea, Sept. 17,
2023 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) announced today a new agreement with Bristol Myers
Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers
Squibb commercial antibody cancer drug substance.
Bristol Myers Squibb and Samsung
Biologics have an existing manufacturing agreement for a commercial
antibody cancer drug and have expanded the strategic relationship
over time. Under the terms of the new agreement, Samsung Biologics
will provide drug substance manufacturing for an antibody cancer
drug substance at the company's latest and largest biomanufacturing
facility, Plant 4, in Songdo, South Korea.
"Our relationship with Bristol Myers Squibb spans over a decade,
and we are proud and excited to help bring important medicines to
patients around the world," said John
Rim, President and CEO of Samsung Biologics. "This
collaboration with Bristol Myers Squibb underscores our commitment
to expediting the delivery and ensuring the continuous supply of
client pipelines, enabled by our commitment to manufacturing
quality, innovation, and capacity."
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated,
end-to-end CDMO service provider, offering seamless development and
manufacturing solutions from cell line development to final aseptic
fill/finish as well as laboratory testing support for the
biopharmaceutical products we manufacture. Our
state-of-the-art facilities are cGMP compliant with bioreactors
ranging from small to large scales to serve varying client needs.
To maximize our operational efficiency and expand our capabilities
in response to growing biomanufacturing demands, Samsung Biologics
fully completed Plant 4, which will further advance the company's
standing as the world's largest manufacturing facility at a single
site—holding a 604KL total capacity—and announced plans to
construct Plant 5, which will be operational in April 2025. Additionally, Samsung Biologics
America enables the company to work in closer proximity to clients
based in the U.S. and Europe. We
continue to expand our capabilities to accommodate our clients by
investing in technologies such as an antibody-drug conjugate (ADC)
facility, a dedicated mRNA manufacturing facility, and additional
aseptic filling capacity. As a sustainable CDMO partner of choice,
we are committed to on-time, in-full delivery of the products with
our flexible development and manufacturing solutions, operational
excellence, and proven expertise.
Samsung Biologics Contact
Head of Marketing Communication
SOURCE Samsung Biologics